Nexalin Technology (NXL) Cash from Investing Activities (2023 - 2026)
Nexalin Technology (NXL) posted quarterly Cash from Investing Activities of $1.5 million for Q1 2026, up 2.44% year-over-year from $1.5 million in Q1 2025, and up 119.05% quarter-over-quarter from $689180.0 in Q4 2025.
Nexalin Technology (NXL) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Nexalin Technology's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 2.44% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at -$96070.0 (down 157.56% YoY), while the FY2025 annual figure was -$131991.0, up 77.15% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $1.5 million, up from $689180.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $1.6 million in Q4 2024, with the low at -$4.5 million in Q3 2024.
- The 4-year median for Cash from Investing Activities is $1.2 million (2023), against an average of $404078.5.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 639.66% in 2024, then jumped 136.25% in 2025.
- Nexalin Technology's Cash from Investing Activities stood at $1.2 million in 2023, then surged by 33.09% to $1.6 million in 2024, then plunged by 57.66% to $689180.0 in 2025, then soared by 119.05% to $1.5 million in 2026.
- Business Quant data shows NXL's Cash from Investing Activities at $1.5 million in Q1 2026, $689180.0 in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.46 Mn |
| Jun 30, 2026 | 1.46 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 689,180.00 |
| Dec 31, 2025 | 689,180.00 |
| Sep 30, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | -3.92 Mn |
| Jun 30, 2025 | -3.92 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 729,314.00 |
| Mar 31, 2024 | 729,314.00 |